The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study
AuthorLee, B; Wong, H-L; Tacey, M; Tie, J; Wong, R; Lee, M; Nott, L; Shapiro, J; Jennens, R; Turner, N; ...
Source TitleAsia Pacific Journal of Clinical Oncology
University of Melbourne Author/sGibbs, Peter; Lee, Belinda; Tacey, Mark; Tie, Jeanne; Lee, Margaret; TURNER, NATALIE; Tran, Ben; Iddawela, Mahesh; Wong, Hui-Li; Wong, Rachel; ...
AffiliationSir Peter MacCallum Department of Oncology
Medical Biology (W.E.H.I.)
Melbourne School of Population and Global Health
Rural Clinical School
Medicine, Western Health
Document TypeJournal Article
CitationsLee, B., Wong, H. -L., Tacey, M., Tie, J., Wong, R., Lee, M., Nott, L., Shapiro, J., Jennens, R., Turner, N., Tran, B., Ananda, S., Yip, D., Richardson, G., Parente, P., Lim, L., Stefanou, G., Burge, M., Iddawela, M. ,... Gibbs, P. (2017). The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 13 (4), pp.314-321. https://doi.org/10.1111/ajco.12639.
Access StatusOpen Access
BACKGROUND: Debate continues regarding the benefits versus risks of initial resection of the primary tumor in metastatic colorectal cancer (mCRC) patients with an asymptomatic primary tumor. Although the benefit of the anti-vascular endothelial growth factor agent bevacizumab alongside first-line chemotherapy in mCRC is established, the impact of bevacizumab on the intact primary tumor (IPT) is less well understood. METHODS: Data from an Australian mCRC registry were used to assess the impact of bevacizumab-based regimens in the presence of an IPT, to see if this differs from effects in resected primary tumor (RPT) patients and to understand the safety profile of bevacizumab in patients with IPT. Progression-free survival (PFS), overall survival (OS) and safety endpoints were analyzed. RESULTS: Of 1204 mCRC patients, 826 (69%) were eligible for inclusion. Bevacizumab use was similar in both arms (IPT (64%) versus RPT (70%)); compared with chemotherapy alone, bevacizumab use was associated with significantly longer PFS (IPT: 8.5 months vs 4.7 months, P = 0.017; RPT: 10.8 months vs 5.8 months, P < 0.001) and OS (IPT: 20 months vs 14.8 months, P = 0.005; RPT: 24.4 months vs 17.3 months, P = 0.004)).1 Bevacizumab use in an IPT was associated with more GI perforations (4.5% vs 1.8%, P = 0.210) but less frequent bleeding (1.5% vs 5.3%, P = 0.050) and thrombosis (1.5% vs 2.7%, P = 0.470), versus chemotherapy alone. Median survival was equivalent between patients that did or did not experience bevacizumab-related adverse events - 20.0 months versus 19.9 months, hazard ratio = 0.98, P = 0.623.1 CONCLUSIONS: The addition of bevacizumab significantly improved survival outcomes in mCRC with an IPT. The occurrence of bevacizumab-related adverse events did not significantly impact survival outcomes.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References
- Medical Biology - Research Publications 
- Surgery (RMH) - Research Publications 
- Melbourne School of Population and Global Health - Research Publications 
- Sir Peter MacCallum Department of Oncology - Research Publications 
- Medicine (Western Health) - Research Publications 
- Rural Clinical School - Research Publications 
- Minerva Elements Records